• View the ADG5206 16-channel multiplexer product page, order samples and evaluation boards and download the data sheet: http://www.analog.com/ADG5206
• View the ADG5207 differential 8:1 multiplexer product page, order samples and evaluation boards and download the data sheet: http://www.analog.com/ADG5207
• Read the Switch and Multiplexer Design Considerations for Hostile Environments technical article: http://www.analog.com/ask_apps_eng_40
• Get support at ADI’s EngineerZone^® online technical support community: http://ez.analog.com/community/switches_multiplexers

The ultra-low (0.35 pC) charge injection of the new multiplexers makes them suitable for data acquisition and sample-and-hold applications, where low glitch and fast settling time are required. The low leakage (20 pA) feature ensures high accuracy and resolution, which is an advantage in audio and video signal routing. The ADG5206 and ADG5207 multiplexers are the latest additions to ADI’s switch and multiplexer protection products portfolio, which also includes the ADG5212 and ADG5213—the industry lowest charge injection and low leakage latch-up proof quad switches.

ADG5206 and ADG5207 Features

• Trench isolation between the N-channel and P-channel transistors of each CMOS switch provides guaranteed latch-up protection
• Operate from ±9 V to ±22 V in applications where the analog signal is bipolar and from +9 V to +40 V in applications where the analog signal is unipolar
• Features 3.5-pF off-source capacitance, 60-MHz -3dB bandwidth, ultra-low charge injection (0.35 pC @ 0 V) and source off leakage (400 pA @ 125 °C) performance.
• Operate equally well in both directions when ON and have an input signal range that extends to the power supplies. In the OFF condition, signal levels up to the supplies are blocked. The switches exhibit break-before-make switching action for use in multiplexer applications.

Pricing and Availability

Samples and evaluation board are currently available.

About Analog Devices

Innovation, performance, and excellence are the cultural pillars on which Analog Devices has built one of the longest standing, highest growth companies within the technology sector. Acknowledged industry-wide as the world leader in data conversion and signal conditioning technology, Analog Devices serves over 60,000 customers, representing virtually all types of electronic equipment. Analog Devices is headquartered in Norwood, Massachusetts, with design and manufacturing facilities throughout the world. Analog Devices is included in the S&P 500 Index. http://www.analog.com

Follow ADI on Twitter at http://www.twitter.com/ADI_News.

To subscribe to Analog Dialogue, ADI's monthly technical journal, visit: http://www.analog.com/subscribe

“We continue to make progress on our late stage clinical programs. We are enrolling our two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients”

“We continue to make progress on our late stage clinical programs. We are enrolling our two pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients,” said Mitchell S. Steiner, MD, CEO of GTx. “We expect to receive topline data from these studies during the second quarter of 2013. In addition, we will begin screening patients this month for our Phase II clinical study of Capesaris^® as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.”

Clinical updates

Enobosarm (Ostarine^®, GTx-024), an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer: GTx is currently enrolling subjects with advanced non-small cell lung cancer in two pivotal Phase III clinical trials, POWER 1 and POWER 2. These international Phase III studies are being conducted in clinical sites in the United States, Europe, and South America. In each of the placebo-controlled, double-blind clinical trials, 300 patients with Stage III or IV non-small cell lung cancer are being randomized to oral daily doses of placebo or enobosarm 3 mg at the time they begin first line standard chemotherapy. The studies are evaluating as co-primary endpoints at three months of treatment the response rates of enobosarm versus placebo on maintaining or improving total lean body mass (muscle) assessed by dual x-ray absorptiometry and improving physical function assessed by the Stair Climb Test. Durability of the drug effect is being evaluated as a secondary endpoint after five months of treatment. Enrollment for both studies is expected to be completed in the fourth quarter of this year, and topline results should be released during the second quarter of 2013.

Capesaris^® (GTx-758), an oral selective estrogen receptor alpha agonist, for secondary hormonal therapy of advanced prostate cancer: GTx is initiating this quarter an open-label clinical study of 75 men with metastatic castration resistant prostate cancer to test three lower doses of Capesaris (125 mg, 250 mg and 500 mg) sequentially in cohorts of 25 patients each. The Phase II 712 clinical trial is designed to assess the effect of Capesaris on serum prostate specific antigen response and prostate cancer progression. The study is expected to provide confirmation of the mechanism of drug action for Capesaris on lowering serum free testosterone levels by increasing serum SHBG in castrated men who failed primary androgen deprivation therapy. The safety and tolerability of lower doses of Capesaris will also be evaluated in these subjects, including the incidence of venous thromboembolic events.

Financial highlights for the quarter ended June 30, 2012

The net loss for the quarter ended June 30, 2012 was $10.4 million compared to a net loss of $10.7 million for the same period in 2011.

Revenue for both the second quarter of 2012 and 2011 was $1.6 million and consisted of net sales of FARESTON^® (toremifene citrate) 60 mg, approved for the treatment of metastatic breast cancer in postmenopausal women.

Research and development expenses for the quarter ended June 30, 2012 were $9.2 million compared to $7.6 million for the same period in 2011. General and administrative expenses for the quarter ended June 30, 2012 were $2.6 million compared to $4.5 million for the same period in 2011.

At June 30, 2012, GTx had cash and short-term investments of $55.9 million.

Conference call

There will be a conference call today at 9:00 a.m. Eastern Time. To listen to the conference call, please dial 866-356-4281 from the United States or Canada or 617-597-5395 from other international locations. The access code for the call is 90153804. A playback of the call will be available from approximately 11:00 a.m. Eastern Time today through August 22, 2012 and may be accessed by dialing 888-286-8010 from the United States or Canada or 617-801-6888 from other international locations and referencing reservation number 54291257. Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the Company’s website at http://www.gtxinc.com.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx's clinical trials for enobosarm (also known as Ostarine^® or GTx-024) and its planned clinical trial of Capesaris^® (GTx-758). GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) that GTx may not be able to obtain required regulatory approvals to commercialize its product candidates in a timely manner or at all; (iii) that clinical trials being conducted by GTx may not be completed on schedule, or at all, or may otherwise be suspended or terminated; or (iv) that GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product candidate development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2012 contains under the heading, "Risk Factors", a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

“Having observed the superior performance of our high- and mid-band mixers, our customers are demanding this product”

The IDT F1102 is a low-power, low-distortion dual 400 - 1000 MHz RF-to-IF mixer that improves IM3 by over 15 dB, while simultaneously reducing power consumption by over 40 percent compared to standard mixers. These performance qualities result in better signal-to-noise ratio (SNR) for improved quality of service (QoS), along with lowered heat dissipation to ease heat-sinking requirements in the densely-populated radio card enclosure (1.15 W at 5 V and up to +43 dBm IP3O). Offering unmatched performance and efficiency, the F1102 is ideal for multi-carrier, multi-mode 4G LTE and EGSM BTS systems.

“Having observed the superior performance of our high- and mid-band mixers, our customers are demanding this product,” said Tom Sparkman, vice president and general manager of the Communications Division at IDT. “Our Zero-Distortion technology enables the customer to increase the radio card’s front-end gain to improve SNR, while simultaneously reducing distortion in the crowded EGSM and U.S. cellular bands. With our broad portfolio of high-performance, low-power variable gain amplifiers (VGAs), industry-leading timing, serial switching, data conversion and data compression products, IDT is a one-stop shop for communications signal chain solutions.”

As with other members of IDT’s mixer family, the F1102 offers fast settling time and a constant local oscillator (LO) input impedance in power-up and -down modes. This allows customers to power-down the mixer between time-division duplex (TDD) receiver slots, further reducing power consumption. In addition, the IDTF1102 can be used with either high-side or low-side injection, and is pin-compatible with existing devices on the market, offering a compelling upgrade option.

Availability

The IDT F1102 is currently sampling to qualified customers and is available in a 36-pin 6x6 mm QFN package. For more information about IDT’s RF signal path solutions, visit www.idt.com/go/RF.

About IDT

Integrated Device Technology, Inc., the Analog and Digital Company™, develops system-level solutions that optimize its customers’ applications. IDT uses its market leadership in timing, serial switching and interfaces, and adds analog and system expertise to provide complete application-optimized, mixed-signal solutions for the communications, computing and consumer segments. Headquartered in San Jose, Calif., IDT has design, manufacturing and sales facilities throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market® under the symbol “IDTI.” Additional information about IDT is accessible at www.IDT.com. Follow IDT on Facebook, LinkedIn, Twitter, and YouTube.

IDT and the IDT logo are trademarks or registered trademarks of Integrated Device Technology, Inc. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50370254&lang=en

“We had a productive second quarter and continued to make progress in each of our programs”

“We had a productive second quarter and continued to make progress in each of our programs,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We are seeking to expand our pipeline through our collaboration with Array BioPharma for the discovery of a novel mutant KIT inhibitor; each of our three current clinical programs continues to advance, and most importantly, we remain on track to announce the results from our pivotal LEAP trial of CO-101 in metastatic pancreatic cancer during the fourth quarter this year.”

2012 Financial Results and Outlook

Clovis reported a net loss of $15.7 million for the second quarter of 2012, and $34.7 million for the first half of 2012. This compares to a net loss of $18.5 million for the second quarter and $26.8 million for the first six months of 2011. Net loss attributable to common stockholders for the second quarter of 2012 was $0.61 per share and $1.45 per share for the year to date, compared to $14.32 per share for the second quarter and $21.07 per share for first six months of 2011.

Research and development expenses totaled $12.6 million for the second quarter and $25.2 million for first half of 2012, compared to $9.7 million for the second quarter and $16.7 million for the first six months of 2011. The increase in research and development expenses over the comparable periods in 2011 was driven by the in-licensing of rucaparib in June 2011, expanded development activities for CO-101 and an increase in internal resources to manage the Company’s development programs.

General and administrative expenses totaled $2.7 million for the second quarter and $5.1 million for the first six months of 2012, compared to $1.7 million for the second quarter and $3.1 million for the first six months of 2011. The increase in general and administrative expenses over the comparable periods in 2011 was primarily due to increased internal resources and third party costs to support the activities associated with being a public company.

Operating expenses for the second quarter of 2012 include $1.2 million of stock compensation expense, compared to $0.3 million of stock compensation expense for the second quarter of 2011. Operating expenses for the first half of 2012 included $2.1 million of stock compensation expense, compared to $0.4 million of stock compensation expense for the first half of 2011.

As of June 30, 2012, Clovis had $176.9 million in cash and cash equivalents and 26.1 million outstanding shares of common stock. The Company continues to expect a cash burn of $67 to $72 million for 2012, and to end the year with approximately $140 million in cash.

Recent highlights for Clovis include the following:

• Initiated a Phase I study of CO-101, the Company’s lipid drug conjugate of gemcitabine, in combination with cisplatin in non-small cell lung cancer (NSCLC);
• Continued enrollment in the dose escalation phase of the US/EU Phase I/II study of CO-1686, the Company’s oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of NSCLC;
• Signed a diagnostic collaboration with Foundation Medicine for the discovery of a companion diagnostic for rucaparib, the Company’s oral, small molecule inhibitor of PARP (poly ADP-ribose polymerase) being explored for use in patients with tumors with defective BRCA function in ovarian and breast cancer;
• Continued enrollment in the dose escalation phase of the Phase I/II monotherapy study of rucaparib;
• Received Orphan Drug Designation for rucaparib from the U.S. Food and Drug Association (FDA) for the treatment of ovarian cancer;
• Announced an agreement with Array BioPharma to discover a novel KIT inhibitor targeting secondary mutations occurring in the majority of gastronintestinal stromal tumor (GIST) patients;

Importantly, the Company continues to expect to announce top-line overall survival results of the pivotal LEAP study of CO-101 in metastatic pancreatic cancer during the fourth quarter of 2012.

Clovis will hold a conference call to discuss second quarter 2012 results this morning, August 8, at 8:30 a.m. ET. The conference call will be simultaneously webcast on the Company’s web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: US participants 866.783.2137, International participants 857.350.1596, passcode: 43655406.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of our companion diagnostics, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics. Clovis Oncology undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Clovis Oncology’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K dated for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

“Our focus remains on achieving increased shareholder value by maximizing returns from existing operations and investments, as well as evaluating potential new projects.”

Second Quarter Results
Net earnings for the second quarter of 2012 were $0.4 million, compared to net earnings of $9.5 million in the second quarter of 2011. Loss from operations was $1.1 million for the second quarter of 2012 compared to earnings from operations of $15.8 million for the second quarter of 2011. Basic and diluted earnings were $0.02 per share for the second quarter of 2012 compared to earnings of $0.36 per share for the second quarter of 2011.

Lakes Entertainment reported second quarter 2012 revenues of $2.5 million, compared to prior-year second quarter revenues of $28.2 million. The decrease in revenues was primarily due to the buy-out of the management agreement for the Four Winds Casino Resort in New Buffalo, Michigan, during June of 2011. Pursuant to the buy-out agreement, the Pokagon Band of Potawatomi Indians paid to Lakes a buy-out fee of approximately $24.5 million. The decrease was partially offset by an increase in fees earned from the management of the Red Hawk Casino near Sacramento, California, during the second quarter of 2012 compared to the second quarter of 2011. Revenues in the current year quarter related to the management of the Red Hawk Casino.

For the second quarter of 2012, Lakes’ selling, general and administrative expenses decreased in comparison to the second quarter of 2011 by approximately $0.4 million to $1.9 million. This decline resulted primarily from decreases in travel and related expenses due to the termination of the Company’s aircraft lease during the fourth quarter of 2011 as well as decreases in payroll and related expenses.

Lakes recognized impairments and other losses of $1.4 million and $0.6 million during the second quarters of 2012 and 2011, respectively. The current quarter impairments and other losses included $0.8 million due to the March 2012 determination that Lakes would not continue to move forward with the casino project with the Jamul Indian Village (“Jamul Tribe”) near San Diego, California, and the termination of Lakes’ agreement with the Jamul Tribe. Also included in impairments and other losses for the three months ended July 1, 2012 were $0.6 million related to costs associated with development plans for the Rocky Gap project which were subsequently revised. The prior year second quarter impairments and other losses were due primarily to uncertainty surrounding the completion of the project with the Jamul Tribe.

Amortization of intangible assets related to the operating casinos was $0.3 million for the second quarter of 2012 compared to $9.2 million for the second quarter of 2011. The decrease in amortization costs related primarily to the buy-out of the management agreement for the Four Winds Casino Resort which resulted in the full amortization of the remaining intangible assets associated with that project during the second quarter of 2011.

Net unrealized gains and losses on notes receivable relate to the Company’s notes receivable from Indian tribes for casino projects that are not yet open, which are adjusted to estimated fair value based upon the current status of the related tribal casino projects and evolving market conditions. There were no net unrealized gains or losses on notes receivable during the second quarter of 2012. In the second quarter of 2011, net unrealized losses on notes receivable were $0.1 million related to the project with the Jamul Tribe due primarily to ongoing issues in the credit markets.

Other income, net, was $1.4 million for the second quarter of 2012 compared to $1.3 million for the second quarter of 2011, a significant portion of which relates to non-cash accretion of interest on the Company’s notes receivable.

The income tax benefit for the second quarter of 2012 was $0.1 million compared to a tax provision of $7.7 million for the second quarter of 2011. Lakes’ income tax benefit in the current year quarter was primarily associated with the Company’s ability to carry back its estimated 2012 taxable loss to a prior year and receive a refund of taxes previously paid. This benefit was partially offset by current income tax provision. Lakes’ income tax provision in the prior year period consisted primarily of current income tax provision.

Six Month Results
Net earnings for the six months ended July 1, 2012 were $2.2 million, compared to net earnings of $10.9 million for the six months ended July 3, 2011. Loss from operations was $2.7 million for the first six months of 2012 compared to earnings from operations of $16.9 million for the first six months of 2011. Basic and diluted earnings were $0.08 per share for the six months ended July 1, 2012 compared to earnings of $0.41 per share for the six months ended July 3, 2011.

Lakes Entertainment reported revenues of $4.5 million for the six months ended July 1, 2012, compared to revenues of $34.1 million in the prior year period. The decrease in revenues was primarily due to the buy-out of the management agreement for the Four Winds Casino Resort during June of 2011. Pursuant to the buy-out agreement, the Pokagon Band of Potawatomi Indians paid to Lakes a buy-out fee of approximately $24.5 million. The decrease was partially offset by an increase in fees earned from the management of the Red Hawk Casino during the first six months of 2012 compared to the first six months of 2011. Revenues in the current year related to the management of the Red Hawk Casino.

For the six months ended July 1, 2012, Lakes’ selling, general and administrative expenses were $4.2 million compared to $4.9 million for the six months ended July 3, 2011. This decline resulted primarily from decreases in travel and related expenses due to the termination of the Company’s aircraft lease during the fourth quarter of 2011 as well as decreases in payroll and related expenses which were partially offset by increases in professional fees.

Lakes recognized impairments and other losses of $2.3 million and $1.5 million during the first six months of 2012 and 2011, respectively. The current year impairments and other losses included $1.7 million due to the March 2012 determination that Lakes would not continue to move forward with the casino project with the Jamul Tribe, and the termination of Lakes’ agreement with the Jamul Tribe. Also included in impairments and other losses for the six months ended July 1, 2012 were $0.6 million related to costs associated with development plans for the Rocky Gap project which were subsequently revised. The prior year impairments and other losses were due primarily to uncertainty surrounding the completion of the project with the Jamul Tribe.

Amortization of intangible assets related to the operating casinos was $0.5 million for the six months ended July 1, 2012 compared to $11.2 million for the six months ended July 3, 2011. The decrease in amortization costs related primarily to the buy-out of the management agreement for the Four Winds Casino Resort which resulted in the full amortization of the remaining intangible assets associated with that project during the second quarter of 2011.

Net unrealized gains and losses on notes receivable relate to the Company’s notes receivable from Indian tribes for casino projects that are not yet open, which are adjusted to estimated fair value based upon the current status of the related tribal casino projects and evolving market conditions. There were no net unrealized gains or losses on notes receivable during the first six months of 2012. During the first six months of 2011, net unrealized gains on notes receivable were $0.6 million related to the project with the Jamul Tribe due primarily to improvements in the credit markets during that period.

Other income, net, was $2.7 million for the six months ended July 1, 2012 compared to $2.6 million for the six months ended July 3, 2011, a significant portion of which relates to non-cash accretion of interest on the Company’s notes receivable.

The income tax benefit for the six months ended July 1, 2012 was $2.1 million compared to a tax provision of $8.7 million for the prior year period. Lakes’ income tax benefit in the current year period was primarily due to the Company’s ability to carry back its estimated 2012 taxable loss to a prior year and receive a refund of taxes previously paid. Lakes’ income tax provision in the prior year period consisted primarily of current income tax provision.

Tim Cope, President and Chief Financial Officer of Lakes stated, "We are pleased that second quarter 2012 results showed improvements over second quarter 2011 at the Red Hawk Casino and we continue to work closely with the property’s executive team, as well as the Shingle Springs Tribal Gaming Authority, to manage this property as efficiently as possible with the goal of continuing this positive trend.” Mr. Cope continued, “As previously announced, we purchased the Rocky Gap Lodge & Golf Resort near Cumberland, Maryland earlier this month. We are very excited to proceed with developing a casino on this property, which we currently expect to open mid-2013. The existing hotel and golf course will remain open throughout the development timeframe.”

Further commenting, Lyle Berman, Chief Executive Officer of Lakes stated, “We continue to maintain a 10% ownership interest in Rock Ohio Ventures, LLC and its casino developments in Cincinnati and Cleveland, Ohio, and we made an additional investment of $4.5 million during the second quarter, bringing our current cash investment to $20.2 million. In May of 2012, the Horseshoe Casino Cleveland opened and we look forward to the opening of the casino in Cincinnati during 2013.” Mr. Berman continued, “Our focus remains on achieving increased shareholder value by maximizing returns from existing operations and investments, as well as evaluating potential new projects.”

About Lakes Entertainment

Lakes Entertainment, Inc. currently has a management agreement with the Shingle Springs Band of Miwok Indians to manage the Red Hawk Casino. Lakes has an investment in Rock Ohio Ventures, LLC’s casino developments in Cincinnati and Cleveland, Ohio. Lakes’ subsidiary Evitts Resort, LLC, has been awarded a video lottery operation license for the Rocky Gap Lodge & Golf Resort it owns near Cumberland, Maryland.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Lakes Entertainment, Inc.) contains statements that are forward-looking, such as statements relating to plans for future expansion and other business development activities as well as other capital spending, financing sources and the effects of regulation (including gaming and tax regulation) and competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the company. These risks and uncertainties include, but are not limited to, need for potential future financing to meet Lakes’ development needs; those relating to the inability to complete or possible delays in completion of Lakes' casino projects, including various regulatory approvals and numerous other conditions which must be satisfied before completion of these projects; possible termination or adverse modification of management or development contracts; Lakes operates in a highly competitive industry; possible changes in regulations; reliance on continued positive relationships with Indian tribes and repayment of amounts owed to Lakes by Indian tribes; possible need for future financing to meet Lakes' expansion goals; risks of entry into new businesses; reliance on Lakes' management and litigation costs. For more information, review the company's filings with the Securities and Exchange Commission.

“We have always believed the Internet is the heart of the new economy. We have already seen Go Daddy products help transform people's aspirations into reality here in India, and it's amazing to see.”

The news comes as Go Daddy India officially announces its customer care facility in Hyderabad, India, which has been in operation since June. A team of local agents, who speak local languages, are now providing Go Daddy's brand of award-winning customer service to Indian customers. Since opening a little more than one month ago, agents have taken more than 10,000 calls, mostly from entrepreneurs and business owners. To date, Go Daddy India now supports more than 120,000 customers.

Leading the expansion is Go Daddy India Managing Director Rajiv Sodhi, who is from Gurgaon, India, and has 14 years' experience in the technology sector, primarily helping small businesses develop their online presence.

"What we are doing is helping people leverage the Internet to grow their businesses ... providing simple products at competitive prices and supporting them with industry-best customer service based here in India. It's a pretty straightforward formula and it works," Sodhi said. "In this economy, everyone is looking for an edge. I think our timing has been exquisite and the results are playing out better than we expected at this point."

In addition to dramatic growth with customers, calls and service, monthly website traffic is rising rapidly, as well, with traffic to in.GoDaddy.com increased by 54 percent, year-over-year.

Go Daddy’s Vice President of International Development Ryan Corder, who is in India for the customer care center's official grand opening this week, said, "We have always believed the Internet is the heart of the new economy. We have already seen Go Daddy products help transform people's aspirations into reality here in India, and it's amazing to see."

PlanMyDay.in, an online remote secretary and productivity services company, is a prime example. What started as an idea and a domain name is now a fully operational, secure website geared toward helping people manage their time better. Small businesses benefit from the wide array of Go Daddy products and services like website design and cloud computing, all fully supported by Go Daddy's top-notch customer service. Go Daddy is fueling growth in India by offering a one-stop shop for small businesses looking to grow their businesses on the Internet.

"Go Daddy believes in the power of the Internet to bridge the digital divide in India. Our products and services empower Indian SMEs to grow their businesses and be the driver behind the Indian economy,” said Sodhi.

This business approach has helped Go Daddy grow to serve more than 10.4 million customers worldwide. Go Daddy also has more than 53 million domain names under management, the largest portfolio in the history of the Internet.

Recently introduced payment options also make it easy to do business with Go Daddy in India. Customers can make payments for online purchases in Indian rupees through Net Banking, various cash cards and mobile devices, in addition to credit cards. These payment options make it convenient for customers to make secure transactions.

To find out more about how to get online easily and affordably, visit www.GoDaddy.com.

Connect with Go Daddy on Facebook & Twitter.

About Go Daddy

Go Daddy is the world's largest domain name provider, Web hosting provider and new SSL certificate provider, focused on helping small businesses grow larger. Go Daddy provides dozens of cloud-based services and is the largest worldwide mass-market hosting provider by annual revenue according to Tier1 Research (Mass-Market Hosting Report-Winter 2011) and is the #1 provider of net-new SSL certificates for 2011, according to the Netcraft, LTD Secure Server Survey. To learn more about the company, visit www.GoDaddy.com/PR.

- Go Daddy Operating Company, LLC -

Copyright © 2012 GoDaddy.com, LLC All Rights Reserved.

“We have grown exponentially since launching our initial website, with an ever expanding portfolio of clients seeking a global service provider”

“We have grown exponentially since launching our initial website, with an ever expanding portfolio of clients seeking a global service provider,” said Suneet Walia, President and CEO of APCER Pharma. “The new site is designed to emphasize our ability to deliver compliant, comprehensive, customized, cost-effective solutions through a unified, highly experienced global team.”

The homepage welcomes visitors to explore the advantages APCER Pharma brings to its partnerships with clients in the pharmaceutical, biotechnology, medical device and consumer products industries. The site’s navigation is organized to clearly delineate the services APCER provides, which includes:

• Clinical Safety and Pharmacovigilance
• Medical Affairs and Communication
• Medical, Clinical, and Regulatory Writing
• Regulatory Strategy and Operations

Visitors can also learn about the company’s integrated technology platform that supports drug safety, medical affairs, and regulatory operations, its experienced leadership team, and its diverse client profiles. In the “Expert Speak” section of the website, APCER will continually post insights and information valuable to pharmacovigilance and compliance professionals.

About APCER Pharma

APCER Pharma is a global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs, and regulatory operations. Its international team of highly experienced healthcare professionals, scientists, and technologists provides pharmaceutical, biotechnology, medical device, and consumer product companies with deep knowledge of worldwide regulations and best practices to comply with them. For more information on APCER Pharma, please call (+1) 609-455-1600, or visit the company website at www.apcerpharma.com.

“Guide to Mitigating Spacecraft Charging Effects. JPL Space Science and Technology Series”

The Definitive Guide To The Modern Body Of Spacecraft Charging Knowledge from First Principles For The Beginner To Intermediate And Advanced Concepts

The only book to blend the theoretical and practical aspects of spacecraft charging, Guide to Mitigating Spacecraft Charging Effects defines the environment that not only creates the aurora, but which also can have significant effects on spacecraft, such as disruption of science measurements and solar arrays from electrostatic discharge (ESD). It describes in detail the physics of the interaction phenomenon as well as how to construct spacecraft to enhance their survivability in the harsh environment of space.

Combining the authors' extensive experience in spacecraft charging (and in their provision of design support to NASA, JPL, the commercial satellite market, and numerous other projects) this incredible book offers both a robust physics background and practical advice for neophytes in the field and experienced plasma physicists and spacecraft engineers.

Key Topics Covered

In addition to containing numerous equations, graphs, tables, references, and illustrations, Guide to Mitigating Spacecraft Charging Effects covers:

- Solar cell technology, especially higher voltage arrays, and the new design approaches that are appropriate for them

- Information about the space plasma environment

- New analytic computer codes to analyze spacecraft charging

- Spacecraft anomalies and failures which emphasized designs that are of greater importance than others

Authors

Henry B. Garrett.

Albert C. Whittlesey.

For more information visit http://www.researchandmarkets.com/research/svkrtk/guide_to_mitigatin

Source: John Wiley and Sons Ltd

Electronic materials are the basis of any device designed for modern applications in e.g. information technology or energy conversion. Investigating and perfecting the properties of materials for electronic uses is the research focus of many institutional and industrial research groups acting worldwide.

A major challenge, however, is to both theoretically model and experimentally prepare these materials with sufficient quality, and to integrate them with adequate control so that these properties can be fully utilized.

This publication summarizes cutting edge research presented at "Frontiers in Electronic Materials", a Nature Conference on Correlation Effects and Memristive Phenomena which took place in 2012.

It comprises of contributions from leading authors in these fields who discuss breakthroughs and challenges in fundamental research as well as prospects for future applications.

Key Topics Covered:

- Electron correlation and unusual quantum effects

- Oxide heterostructures and interfaces

- Multiferrroics, spintronics, ferroelectrics and flexoelectrics

- Processing in nanotechnology

- Advanced characterization techniques

- Superionic conductors, thermoelectrics, photovoltaics

- Chip architectures and computational concepts

Authors

Jörg Heber.

Darrell Schlom.

Yoshinori Tokura.

Rainer Waser.

Matthias Wuttig.

For more information visit http://www.researchandmarkets.com/research/vvpzc8/frontiers_of_elect

Source: John Wiley and Sons Ltd

“Fundamentals of the Finite Element Method for Heat and Flow”

The heavily revised and extended second edition offers a complete text and reference book to this well-established approach to the numerical solution of heat transfer and fluid flow problems

This 2nd edition is much extended, and is much improved as both a reference and textbook for research and training. It includes a total of 8 new chapters on the topics of radiation heat transfer, heat exchangers, mass transfer, solidification and melting, turbulent heat transfer, adaptive finite element methods, new applications such as fuel cell modelling and special topics of particular interest to heat transfer engineers such as micro-heat transfer equipments and micro-channel flows. These new topics, along with examples of their applications, serve to further illustrate the capabilities and versatility of the finite element method and educate the reader as to the state-of-the-art of the science and technologies involved. All chapters feature new examples and exercises.

Key Features

- Appropriate for teaching and research at both fundamental and advanced levels

- Presents several examples of applications of the finite element method that will be of interest to both students and practitioners

- Includes a large number of examples and exercises on heat transfer problems

Authors

Perumal Nithiarasu.

Roland W. Lewis.

For more information visit http://www.researchandmarkets.com/research/2r6qfs/fundamentals_of_th

Source: John Wiley and Sons Ltd

“Fundamentals of the Finite Element Method for Heat and Flow”

The heavily revised and extended second edition offers a complete text and reference book to this well-established approach to the numerical solution of heat transfer and fluid flow problems

This 2nd edition is much extended, and is much improved as both a reference and textbook for research and training. It includes a total of 8 new chapters on the topics of radiation heat transfer, heat exchangers, mass transfer, solidification and melting, turbulent heat transfer, adaptive finite element methods, new applications such as fuel cell modelling and special topics of particular interest to heat transfer engineers such as micro-heat transfer equipments and micro-channel flows. These new topics, along with examples of their applications, serve to further illustrate the capabilities and versatility of the finite element method and educate the reader as to the state-of-the-art of the science and technologies involved. All chapters feature new examples and exercises.

Key Features

- Appropriate for teaching and research at both fundamental and advanced levels

- Presents several examples of applications of the finite element method that will be of interest to both students and practitioners

- Includes a large number of examples and exercises on heat transfer problems

Authors

Perumal Nithiarasu.

Roland W. Lewis.

For more information visit http://www.researchandmarkets.com/research/2r6qfs/fundamentals_of_th

Source: John Wiley and Sons Ltd

“Case Studies in Modern Drug Discovery and Development”

Using case studies of successful drug discoveries and launches, this book helps master the necessary knowledge of the drug discovery process. It includes pharmacology, drug metabolism, biology, drug development, and clinical studies. The introduction provides an overview of process, principles, and technologies and each chapter contains case studies that focus on one therapeutic target. It also offers stories from patients who have used the drugs covered as a way to illustrate the impact medicinal chemistry has on real life.

Key Topics Covered:

CHAPTER 1 INTRODUCTION: DRUG DISCOVERY IN DIFFICULT TIMES

CHAPTER 2 DISCOVERY AND DEVELOPMENT OF THE DPP-4 INHIBITOR JANUVIA(SITA-GLIPTIN)

CHAPTER 3 OLMESARTAN MEDOXOMIL: AN ANGIOTENSIN II RECEPTOR BLOCKER

CHAPTER 4 DISCOVERY OF HETEROCYCLIC PHOSPHONIC ACIDS AS NOVELAMPMIMICS THAT ARE POTENT AND SELECTIVE FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS AND ELICIT POTENT GLUCOSE-LOWERING EFFECTS IN DIABETIC ANIMALS AND HUMANS

CHAPTER 5 SETTING THE PARADIGM OF TARGETED DRUGS FOR THE TREATMENT OF CANCER: IMATINIB AND NILOTINIB, THERAPIES FOR CHRONIC MYELOGENOUS LEUKEMIA

CHAPTER 6 AMRUBICIN, A COMPLETELY SYNTHETIC 9-AMINOANTHRACYCLINE FOR EXTENSIVE-DISEASE SMALL-CELL LUNG CANCER

CHAPTER 7 THE DISCOVERY OF DUAL IGF-1R AND IR INHIBITOR FQIT FOR THE TREATMENT OF CANCER

CHAPTER 8 DISCOVERY AND DEVELOPMENT OF MONTELUKAST (SINGULAIR&reg)

CHAPTER 9 DISCOVERY AND DEVELOPMENT OF MARAVIROC, A CCR5 ANTAGONIST FOR THE TREATMENT OF HIV INFECTION

CHAPTER 10 DISCOVERY OF ANTIMALARIAL DRUG ARTEMISININ AND BEYOND

CHAPTER 11 DISCOVERY AND PROCESS DEVELOPMENT OF MK-4965, A POTENT NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR

CHAPTER 12 DISCOVERY OF BOCEPREVIR AND NARLAPREVIR: THE FIRST AND SECOND GENERATION OF HCV NS3 PROTEASE INHIBITORS

CHAPTER13 THE DISCOVERYOFSAMSCA (TOLVAPTAN):THEFIRST ORAL NONPEPTIDE VASOPRESSIN RECEPTOR ANTAGONIST

CHAPTER 14 SILODOSIN

CHAPTER 15 RALOXIFENE: A SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)

APPENDIX I SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT PARADIGM

APPENDIX II GLOSSARY

APPENDIX III ABBREVIATIONS

Author

Xianhai Huang.

Robert G. Aslanian.

For more information visit http://www.researchandmarkets.com/research/tqh6b4/case_studies_in_mo

Source: John Wiley and Sons Ltd

Net Asset Value(s)

World Trust Fund announces that its unaudited Net Asset Value (NAV) per share in US Dollars, based on the closing prices of 08/07/2012 was $3.33 (Sterling equivalent rate being £2.13).

It is unaudited and Fully Diluted Net Asset Value (NAV) per share in US Dollars was $3.32 (Sterling equivalent rate being £2.12).

Both NAV’s were calculated inclusive of current period income.

Listing Category: Premium - Equity Closed-ended Investment Funds

Forensic Botany: A Practical Guide is an accessible introduction to the way in which botanical evidence is identified, collected and analysed in criminal cases. Increasingly this form of evidence is becoming more important in forensic investigation, this book is intended to show how useful simple collection methods and standard plant analysis can be in the course of such investigations and is written in a clear and accessible manner to enhance understanding of the subject for the non-specialist.

Clearly structured throughout, this book combines well known collection techniques in a field oriented format that can be used for casework. Various methods that allow easy collection, transportation, and preservation of evidence are detailed throughout the book.

Key Features

The format of the book is designed to present the reader with all the information needed to conduct a botanical analysis of a crime scene; to highlight the forensic significance of the botanical evidence that may be present; how to collect that evidence in the correct manner and preserve and store that evidence appropriately - also shows how to conduct a laboratory analysis of the plants.

- An accessible practical guide to the collection, analysis and presentation of botanical evidence within forensic investigation.

- Aimed at the non-specialist looking for an introduction to the field.

- Written in a clear and logical manner; what is it? Where can you find help? How can you use plant evidence? Why is this kind of plant important? Where to look for evidence; Evidence collection made easy; evidence preservation; evidence transportation; Chain of custody.

- Includes evidence collection data sheet and a laboratory analysis data sheet for use in the field.

- Includes key chapters on microscopy analysis of plant evidence and on DNA collection, use and relative costs.

- Numerous relevant case studies included to show forensic botany in practice and how to present botanical evidence in court.

Readership

This book is written for those who have no formal background working with plants. It can be used as a practical guide for students taking forensic science courses, law enforcement training, legal courses, and as a template for plant collection at any scene where plants occur and where rules or laws are involved. Veterinarians, various environmental agencies and anthropologists are examples of disciplines that are more recently in need of plant evidence.

Authors

David Hall.

Jason Byrd.

For more information visit http://www.researchandmarkets.com/research/3f92sl/forensic_botany_a

Source: John Wiley and Sons Ltd

“Data Mining in Drug Discovery. Methods and Principles in Medicinal Chemistry”

From tools to applications, this is a systematic approach to mining chemical, biological and literature data sources for drug discovery purposes. Throughout, industrial and academic drug discovery strategies are addressed, with contributors coming from both areas.

Key Topics Covered:

Introduction

DATA SOURCES

- Databases of Organic Compounds

- Protein Databases

- Databases for Protein-Protein Interactions

- Combining Chemistry and Biology

- Ontologies and Data Mining

Data Mining Tools:

- Chemistry and Biology 1: Knime

- Chemistry and Biology 2: Accelrys

- Chemistry and Biology 3: Inforsense

- Chemistry and Biology 4: Tibco/Spotfire

- Statistical Tools and Open Source Codes for Medicinal Chemistry: R, Weka, Rapid Miner

- Discovery/Polypharmacology 1: Tripos

- Discovery/Polypharmacology 2: Ariana Pharma

Applications:

- Data Mining and Screening

- Exploiting Systems Chemical Biology to Predict and Understand (Un)desired Drug Effects

- Micro-Arrays

- High Throughput Computational Biology

- Translational Medicine and Personalized Medicine

Authors:

Rémy D. Hoffmann.

Arnaud Gohier.

Raimund Mannhold.

Hugo Kubinyi.

Gerd Folkers.

For more information visit http://www.researchandmarkets.com/research/wtbgfm/data_mining_in_dru

Source: John Wiley and Sons Ltd

A Unique, Practical Approach To The Design Of High-Speed Digital Circuit Boards

The demand for ever-faster digital circuit designs is beginning to render the circuit theory used by engineers ineffective. Digital Circuit Boards presents an alternative to the circuit theory approach, emphasizing energy flow rather than just signal interconnection to explain logic circuit behavior.

The book shows how treating design in terms of transmission lines will ensure that the logic will function, addressing both storage and movement of electrical energy on these lines. It covers transmission lines in all forms to illustrate how trace geometry defines where the signals can travel, then goes on to examine transmission lines as energy sources, the true nature of decoupling, types of resonances, ground bounce, cross talk, and more.

Key Features

Providing designers with the tools they need to lay out digital circuit boards for fast logic and to get designs working the first time around, Digital Circuit Boards:

- Reviews in simple terms the basic physics necessary to understand fast logic design

- Debunks the idea that electrical conductors carry power and signals, showing that signal travels in the spaces, not the traces, of circuit boards

- Explains logic circuit behavior through real-time analysis involving the fields and waves that carry signal and energy

- Provides new information on how ground/power planes work

- Outlines a software program for solving energy flow in complex networks

Author

Ralph Morrison.

For more information visit http://www.researchandmarkets.com/research/5229zg/digital_circuit_bo

Source: John Wiley and Sons Ltd

Evolution of Virulence in Eukaryotic Microbes offers a unique and up-to-date review of eukaryotic virulence in fungi, oomycetes, and protozoa parasites and how they affect both animals and plants. The only book to combine a discussion of human and plant pathogens, it takes a fresh look at the selective processes that have shaped the evolution of these organisms. Written by the world's top leaders in this area, the book explores advances in genetic tools, how pathogens exchange genetic material in nature, and the common themes of evolutionary adaptation that lead to disease in different hosts.

Key Topics Covered:

PART I GENERAL OVERVIEWS

- Population Genetics and Parasite Diversity

- Evolution of Meiosis, Recombination, and Sexual Reproduction in Eukaryotic Microbes

- Phylogenomic Analysis

- Phylogenetics and Evolution of Virulence in the Kingdom Fungi

PART II POPULATION GENETICS AND EVOLUTIONARY APPROACHES

- Malaria: Host Range, Diversity, and Speciation

- From Population Genomics to Elucidated Traits in Plasmodium Falciparum

- Selective Sweeps in Human Malaria Parasites

- Evolution of Drug Resistance in Fungi

- Discovery of Extant Sexual Cycles in Human Pathogenic Fungi and Their Roles in the Generation of Diversity and Virulence 1

- Worldwide Migrations, Host Shifts, and Reemergence of Phytophthora Infestans, the Plant Destroyer

- Experimental and Natural Evolution of the Cryptococcus Neoformans and Cryptococcus Gattii Species Complex

- Population Genetics, Diversity, and Spread of Virulence in Toxoplasma Gondii

PART III FORWARD AND REVERSE GENETIC SYSTEMS FOR DEFINING VIRULENCE

- Genetic Crosses in Plasmodium Falciparum: Analysis of Drug Resistance

- Genetic Mapping of Virulence in Rodent Malarias

- Genetic Mapping of Acute Virulence in Toxoplasma Gondii

- Virulence in African Trypanosomes: Genetic and Molecular Approaches

- The Evolution of Antigenic Variation in African Trypanosomes

- Antigenic Variation, Adherence, and Virulence in Malaria

- Invasion Ligand Diversity and Pathogenesis in Blood-Stage Malaria

PART IV COMPARATIVE "OMICS" APPROACHES TO DEFINING VIRULENCE

- Evolution of Virulence in Oomycete Plant Pathogens

- Evolution and Genomics of the Pathogenic Candida Species Complex

- Evolution of Entamoeba Histolytica Virulence

- Sex and Virulence in Basidiomycete Pathogens

- Emergence of the Chytrid Fungus Batrachochytrium Dendrobatidis and Global Amphibian Declines

- Impact of Horizontal Gene Transfer on Virulence of Fungal Pathogens of Plants

- Evolution of Plant Pathogenicity in Fusarium Species

- Genetic, Genomic, and Molecular Approaches to Define Virulence of Aspergillus Fumigatus

- Cryptosporidium: Comparative Genomics and Pathogenesis

Authors:

L. David Sibley.

Barbara J. Howlett.

Joseph Heitman.

For more information visit http://www.researchandmarkets.com/research/f33l8p/evolution_of_virul

Source: John Wiley and Sons Ltd

The use of additives in food is dynamic, as consumers demand fewer additives in foods and governments review the list of additives approved and their permitted levels. Scientists also refine the knowledge of the risk assessment process and improve alternative additives, processes or ingredients. The revised second edition of this major reference work covers all the "must-have" technical data on food additives. Compiled by food industry experts with a proven track record of producing high quality reference work, this volume is the definitive resource for technologists using food additives.

Key Topics Covered:

Part 1 Acidulants.

Part 2 Antioxidants.

Part 3 Colourings.

Part 4 Emulsifiers.

Part 5 Enzymes.

Part 6 Flavour Enhancers.

Part 7 Flour Additives.

Part 8 Gases.

Part 9 Nutritive Additives.

Part 10 Polysaccharides.

Part 11 Preservatives.

Part 12 Sequestrants.

Part 13 Solvents.

Part 14 Sweeteners.

Author

Jim Smith.

Lily Hong-Shum.

For more information visit http://www.researchandmarkets.com/research/sx32v8/food_additives_dat

Source: John Wiley and Sons Ltd

Playing a key role in cell function and transport, mitotic kinesins are a promising drug target in cancer and other diseases. Featuring contributions from editors and authors on the frontlines of kinesin drug discovery, Targeting Mitotic Kinesins in Drug Discovery covers the fundamentals, approaches, and current clinical status of drugs targeting mitotic kinesins. This comprehensive resource provides pharmaceutical scientists, medicinal chemists, biochemists, pharmacologists, structural and cell biologists, and researchers with in-depth coverage of the medicinal chemistry, biochemistry, and cell biology of agents targeting mitotic kinesins.

Authors

Xiangping Qian.

Daniel W Pierce.

For more information visit http://www.researchandmarkets.com/research/x5r9jd/targeting_mitotic

Source: John Wiley and Sons Ltd

“Door te kijken naar de projecten waarbij we samenwerkten met onze klanten, wist iedereen bij IQMS dat we samenwerkten met pioniers, maar we waren zeer onder de indruk van de omvang van de projecten”

Dit is het eerste jaar dat de IQMS Manufacturing Success Awards worden uitgereikt. Deze zijn in het leven geroepen ter erkenning van een industrieel project of een initiatief dat een inzet toont tot succes in de industrie en de verbetering van het bedrijf. Er zijn een groot aantal inzendingen binnengekomen van fabrikanten over de hele wereld. Dit geeft aan dat de klanten van IQMS daadwerkelijk bezig zijn met het veranderen van het productielandschap binnen hun verschillende industrieën. De IQMS Manufacturing Success Highest Achiever zal bekend worden gemaakt tijdens IQMS' User Group 2012 conferentie op 16 oktober 2012 in Las Vegas, Nevada (VS). De top vijf finalisten zijn:

• Gill Industries, Inc. heeft de indeling van zijn werkvloer volledig vernieuwd en daarna die nieuwe flow gebruikt (in combinatie met de ERP en MES productiesoftware van IQMS) om inventarisplaatsen en verplaatsingen te behalen die nauwkeurige, realtime informatie opleverden voor de hele organisatie.
• Miniature Precision Components, Inc. (MPC) implementeerde een 3-stappenplan om af te slanken (installatie van een nieuw lopende bandsysteem, invoering van productie-meldstations en instelling van een uitvoeringssysteem voor onderdelen) om een verouderde logistieke situatie te verbeteren.
• Plastic Components, Inc. (PCI) heeft recentelijk een volledige "lichten uit"-fabriek gecreëerd die werkt zonder menselijk ingrijpen van het centrale afhandelingsysteem voor materialen tot het automatische lopende bandsysteem voor dozen; gebruik makend van software en netwerkcamera's van IQMS.
• Plastikos, Inc. heeft een automatisch productie-etikettering en volgproces voor gereedschap gecreëerd dat onder meer drukstations voor etiketten bevat, waarbij gebruik gemaakt wordt van geautomatiseerde, realtime productierapportage bij de drukpers en het instellen van geautomatiseerde volgmogelijkheden voor gereedschap door het gebruik van barcodelabels met behulp van IQMS-technologie.
• Tessy Plastics Corporation heeft, in samenwerking met de Automation groep van IQMS, Bills of Materials (BOMs) rechtstreeks geïntegreerd in haar assemblage PLCs voor automatische validering van onderdelen, om nauwkeurige informatie te verzekeren over de onderdelen en kostbare assemblagefouten te elimineren wanneer haar robots producten aan het assembleren waren.

“Door te kijken naar de projecten waarbij we samenwerkten met onze klanten, wist iedereen bij IQMS dat we samenwerkten met pioniers, maar we waren zeer onder de indruk van de omvang van de projecten," aldus Randy Flamm, CEO van IQMS. "De nominaties die wij ontvingen van zowel grote als kleine bedrijven die gespecialiseerd zijn in elke industrie die wij bedienen, toonden aan dat onze klanten daadwerkelijk invloedrijke, indrukwekkende productieleiders zijn. Wij zijn er trots op dat we onderdeel uitmaken van hun succes en dat we deze kans kunnen bieden om successen te vieren."

Om een onpartijdige omgeving te kunnen waarborgen heeft IQMS een externe commissie aangesteld bestaande uit deskundige juryleden om de winnaar van 2012 te selecteren. Predrag (PJ) Jakovljevic, hoofdanalist bij Technology Evaluation Centers, Jeff Mengel, partner bij Plante & Moran, Gary Mintchell, mede-oprichter en hoofdredacteur van Automation World, en R “Ray” Wang, hoofdanalist en CEO bij Constellation Research, Inc. hebben hun tijd, kennis van de industrie en inzicht aangeboden om een winnaar te selecteren.

Ga voor meer informatie over de finalisten van de IQMS Manufacturing Success Award, en voor een beter inzicht in hun nominaties naar: http://www.iqms.com/manufacturing-award/

Over IQMS

Sinds 1989 heeft IQMS ERP-productiesoftware voor de repetitieve-, proces- en discrete industrie ontworpen en ontwikkeld. Tegenwoordig biedt IQMS een uitgebreide realtime MES- en ERP-productiesoftwareoplossing voor de automobiel-, medische-, verpakkings-, consumentengoederen- en andere productiemarkten. De innovatieve, single-database enterprise softwareoplossing, EnterpriseIQ, biedt een schaalbaar systeem dat ontworpen is om gemakkelijk met de klant mee te groeien met volledige bedrijfsfunctionaliteit, waaronder boekhouding, kwaliteitscontrole, toelevering, CRM en eBusiness. Met kantoren in Noord-Amerika, Europa en Azië, bedient IQMS producenten over de hele wereld.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

This book presents a comprehensive and substantial overview of the emerging field of food safety engineering, bringing together in one volume the four essential components of food safety:

- the fundamentals of microbial growth

- food safety detection techniques

- microbial inactivation techniques

- food safety management systems

Written by a team of highly active international experts with both academic and professional credentials, the book is divided into five parts.

Part I details the principles of food safety including microbial growth and modelling.

Part II addresses novel and rapid food safety detection methods.

Parts III and IV look at various traditional and novel thermal and non-thermal processing techniques for microbial inactivation.

Part V concludes the book with an overview of the major international food safety management systems such as GMP, SSOP, HACCP and ISO22000.

Key Topics Covered:

PART ONE: FUNDAMENTALS

• 1 Introduction to Food Microbiology
• 2 Overview of Foodborne Pathogens
• 3 Chemical Safety of Foods
• 4 Intrinsic and Extrinsic Parameters for Microbial Growth and Heat Inactivation
• 5 Kinetics of Microbial Inactivation
• 6 Predictive Microbial Modelling
• 7 Integration of Food Process Engineering and Food Microbial Growth

PART TWO: ADVANCED FOOD SAFETY DETECTION METHODS

• 8 Rapid Methods and Automation in Microbiology: 30 Years of Trends and Predictions
• 9 Phage-based Detection of Foodborne Pathogens
• 10 Real-time PCR
• 11 DNA Array
• 12 Immunoassay
• 13 Biosensors

PART THREE: CONVENTIONAL PROCESSING SYSTEMS OF PRODUCING SAFE FOODS

• 14 Pasteurization and Sterilization
• 15 Microwave Processing
• 16 Drying of Foods
• 17 Frying of Foods
• 18 Food Refrigeration
• 19 Sous Vide and Cook-chill Processing
• 20 Irradiation
• 21 Aseptic Processing and Packaging
• 22 Modified Atmosphere Packaging

PART FOUR: NOVEL PROCESSING METHODS FOR FOOD MICROBIAL INACTIVATION

• 23 High Pressure Processing
• 24 Pulsed Electric Field Processing
• 25 Radio Frequency Technology
• 26 Pulsed Light Technology
• 27 Ohmic Heating Treatment
• 28 Ozone Processing
• 29 Intelligent Packaging

PART FIVE: FOOD SAFETY MANAGEMENT SYSTEMS

• 30 Introduction to Food Safety Management
• 31 Good Manufacturing Practice (GMP)
• 32 Sanitation Standard Operating Procedures
• 33 Hazard Analysis Critical Control Point (HACCP) System
• 34 ISO 22000 Food Safety

Author

Da-Wen Sun.

For more information visit http://www.researchandmarkets.com/research/tjkpgx/handbook_of_food_s

Source: John Wiley and Sons Ltd

« Sur la base des projets auxquels nous avons collaboré avec nos clients, tout le monde chez IQMS savait que nous avions comme partenaires des innovateurs, mais nous avons été vraiment impressionnés par l'ampleur des projets »

Le concours IQMS Manufacturing Success Awards, dont c'est la première édition, a été créé pour récompenser un projet de fabrication ou une initiative susceptible d'assurer le succès d'une activité ou d'améliorer les processus commerciaux. Des fabricants du monde entier ont soumis des dizaines de projets et démontré que les clients de IQMS sont effectivement en train de changer le paysage du secteur manufacturier dans leurs diverses industries. Le lauréat de ce IQMS Manufacturing Success Award, ou concours des meilleurs fabricants, sera annoncé lors de la Conférence 2012 du groupe des utilisateurs d'IQMS prévue pour le 16 octobre 2012 à Las Vegas dans le Nevada Voici les cinq meilleurs projets retenus comme finalistes :

• Gill Industries, Inc. a complètement remanié l'ordonnancement de son atelier et a utilisé ensuite le nouveau flux (en combinaison avec les progiciels de fabrication ERP et MES d'IQMS) pour agencer les emplacements et mouvements des stocks de manière à fournir en temps réel des informations précises à l'échelle de l'entreprise.
• Miniature Precision Components, Inc. (MPC) a mis en œuvre une initiative de rationalisation en trois phases (installation d'un nouveau système de convoyeur, déploiement de stations d'évaluation de la production et établissement d'un système d'exécution des pièces) pour améliorer une situation logistique obsolète.
• Plastic Components, Inc. (PCI) a récemment inauguré une usine de fabrication entièrement automatisée qui fonctionne sans intervention humaine depuis le système centralisé de manutention jusqu'au système de transport automatisé en utilisant les progiciels de IQMS et des caméras en réseau.
• Plastikos, Inc. a créé un processus d'étiquetage de production et de suivi d'outil qui comprenait le déploiement de stations d'impression des étiquettes et leur coordination automatisée avec les rapports de production en temps réel. Un suivi automatisé des outils à l'aide d'étiquettes à codes barre a également été mis en place grâce à la technologie IQMS.
• En collaboration avec le groupe d'automatisation d'IQMS, Tessy Plastics Corporation a intégré ses nomenclatures de pièces directement dans ses automates d'assemblage afin de valider automatiquement les pièces et garantir l'exactitude des données relatives aux composants, ce qui élimine les erreurs de montage coûteuses alors que ses robots assemblent les marchandises.

« Sur la base des projets auxquels nous avons collaboré avec nos clients, tout le monde chez IQMS savait que nous avions comme partenaires des innovateurs, mais nous avons été vraiment impressionnés par l'ampleur des projets », a déclaré Randy Flamm, PDG de IQMS. « Les candidatures que nous avons reçues aussi bien des grandes que des petites entreprises qui se spécialisent dans chacun des secteurs où nous opérons nous ont démontré que nos clients sont vraiment des acteurs influents et des leaders de la fabrication. Nous sommes fiers de participer à leur succès et d'offrir cette opportunité de célébrer leurs réalisations ».

Afin de garantir une évaluation impartiale, IQMS a engagé un panel externe de juges experts pour sélectionner le candidat 2012 le plus performant. Predrag (PJ) Jakovljevic, analyste principal chez Technology Evaluation Centers, Jeff Mengel, partenaire associé chez Plante & Moran, Gary Mintchell, co-fondateur et rédacteur en chef de Automation World, et R « Ray » Wang, analyste principal et chef de la direction chez Constellation Research, Inc. ont généreusement offert leur temps, leur expertise professionnelle et leurs avis informés dans le choix du lauréat.

Pour plus d'informations sur les finalistes des IQMS Manufacturing Success Award et un examen approfondi des projets soumis, veuillez consulter le site : http://www.iqms.com/manufacturing-award/

À propos d’IQMS

Depuis 1989, IQMS conçoit et développe un progiciel de gestion intégré (ERP) pour l’industrie destiné aux secteurs de la fabrication répétitive, de la transformation et de la production d’unités séparées. Aujourd’hui, IQMS fournit des progiciels MES et ERP complets en temps réel destinés aux marchés de l’automobile, des appareils médicaux, du conditionnement, des produits de consommation et à d'autres marchés de la fabrication. EnterpriseIQ, la solution logicielle d'entreprise innovante à base de données unique, offre un système évolutif conçu pour se développer en parfait accord avec les besoins du client et une fonctionnalité métier complète couvrant la comptabilité, le contrôle de la qualité, la chaîne logistique, la gestion de la relation client et les affaires électroniques. IQMS, qui possède des bureaux dans toute l’Amérique du Nord, l’Europe et l’Asie, compte parmi ses clients des fabricants du monde entier.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

„Aufgrund der Projekte, an denen wir gemeinsam mit unseren Kunden arbeiten, ist jedem bei IQMS bewusst, dass wir Innovatoren als Partner zur Seite stehen. Dennoch waren wir von der Bandbreite der Projekte nicht wenig überrascht“

Im Jahr der erstmaligen Vergabe sollten mit den neu ins Leben gerufenen IQMS Manufacturing Success Awards Projekte im Bereich der Fertigungstechnik oder Initiativen ausgezeichnet werden, die sich um den Branchenerfolg verdient gemacht haben und zu nennenswerten Verbesserungen des Geschäfts geführt haben. Es wurden Dutzende Vorhaben von Fertigungsunternehmen aus aller Welt eingereicht. Dies zeigt, dass die Kunden von IQMS tatsächlich die Fertigungslandschaft in ihren jeweiligen Branchen verändern. Die höchste Auszeichnung bei den IQMS Manufacturing Success Awards wird am 16. Oktober 2012 auf der Konferenz der IQMS-Anwendergruppen in Las Vegas im Bundesstaat Nevada bekannt gegeben. Die fünf für das Finale nominierten Projekte sind:

• Gill Industries Inc. gestaltete das Layout seines Fertigungsbereiches vollständig um. Mithilfe des neuen Materialflusses (in Kombination mit den Angeboten an Fertigungs-ERP- und MES-Software von IQMS) wurden Lagerorte zugewiesen und -bewegungen erfasst, sodass im gesamten Unternehmen für einen fehlerfreien Echtzeit-Informationsfluss gesorgt wurde.
• Miniature Precision Components, Inc. (MPC) implementierte zur Verbesserung seiner nicht mehr den modernen Standards entsprechenden Logistik im Zuge einer Lean-Initiative drei neue Komponenten (Installation eines neuen Materialfördersystems, Einführung einer Produktionsberichtserstattung, Einrichtung eines Teile-Ausführungssystems).
• Plastic Components, Inc. (PCI) baute vor Kurzem eine Fertigungsanlage, die quasi „lichtlos“ betrieben wird. Diese wird ohne menschliches Eingreifen vor Ort vom zentralen Materialzuführungssystem aus über dessen automatische Steuerung bedient, die mit Software von IQMS und Netzwerkkameras arbeitet.
• Plastikos, Inc. entwickelte einen automatisierten Prozess zur Produktionsbeschriftung und Werkzeugrückverfolgung. Dieser umfasste die Einrichtung von Beschriftungsstationen an der Presse, die Meldung von Produktionsdaten in Echtzeit an der Presse und die Einführung einer automatisierten Werkzeugrückverfolgung durch Barcodelabels mithilfe der Technologie von IQMS.
• Tessy Plastics Corporation integrierte in Zusammenarbeit mit der Automatisierungsabteilung von IQMS Materiallisten direkt in die SPS zur automatischen Validierung von Teilen. Hierdurch wird eine exakte Informationserfassung der Komponenten gewährleistet. Teure Fehler bei der Robotermontage der Produkte werden so vermieden.

„Aufgrund der Projekte, an denen wir gemeinsam mit unseren Kunden arbeiten, ist jedem bei IQMS bewusst, dass wir Innovatoren als Partner zur Seite stehen. Dennoch waren wir von der Bandbreite der Projekte nicht wenig überrascht“, sagte Randy Flamm, CEO bei IQMS. „Sowohl von großen als auch kleinen Unternehmen, die sich in unseren Kundenbranchen spezialisiert haben, haben wir Vorschläge erhalten, die bewiesen, dass unsere Kunden wirklich zu den richtungsweisenden und einflussreichen Unternehmen der Fertigungsindustrie gehören. Wir freuen uns, zu diesen Erfolgen mit beigetragen zu haben und nun bei dieser Gelegenheit die herausragenden Leistungen zu feiern.“

Um eine unparteiische Bewertung vorzunehmen, beauftragte IQMS eine externe Experten-Gruppe, die den Gewinner 2012 bestimmt. Diese Auswahl wurde von Predrag (PJ) Jakovljevic, Chefanalyst bei Technology Evaluation Centers, Jeff Mengel, Partner bei Plante & Moran, Gary Mintchell, Mitgründer und Chefredakteur von Automation World, und R “Ray” Wang, Chefanalyst und CEO bei Constellation Research, Inc. getroffen. Hierfür stellten sie großzügig ihre Zeit, Branchenkenntnis und ihr fundiertes Allgemeinwissen zur Verfügung.

Weiterführende Information über die Finalisten des IQMS Manufacturing Success Awards erhalten sie unter http://www.iqms.com/manufacturing-award/

Über IQMS

Seit 1989 entwirft und entwickelt IQMS ERP-Software für Branchen in der Fließband-, Prozess- und diskreten Fertigung. Heute liefert IQMS eine umfassende Echtzeitlösung als MES- und ERP-Software für Fertigungsbetriebe in der Automobilindustrie, der Medizinbranche, der Verpackungs-, Verbrauchsgüter- und weiteren Fertigungsindustrien. EnterpriseIQ, die innovative, auf einer einzigen Datenbank beruhende Softwarelösung für Unternehmen, bietet ein skalierbares System, das geschickt so konstruiert wurde, dass es zusammen mit dem Kunden wächst und komplette Funktionalität für sämtliche Betriebszwecke bietet, wie etwa Buchhaltung, Qualitätssicherung, Lieferkette, CRM und E-Business. Mit Niederlassungen in ganz Nordamerika, Europa und Asien bedient IQMS Fertigungsbetriebe auf der ganzen Welt.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

Meerwind is een tachtig turbine tellend, 288 Megawatt windmolenpark dat zo'n vijftig kilometer van de Duitse kust in de Noordzee wordt gebouwd. Eenmaal klaar, zal Meerwind schone energie produceren voor zo'n 360 duizend huishoudens and zal Duitsland helpen bijna een miljoen ton aan koolstofuitstoot te verminderen.

Sinds augustus vorig jaar, toen Meerwind het eerste Duitse offshore windmolenpark was dat de financiering als onderdeel van de innovatieve KfW offshore windprogramma, heeft WindMW nauwe samengewerkt met leveranciers om de constructiefase voor te bereiden.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.